Skip to main content

Table 3 ApoB levels, LDL-C levels, and concordance/discordance between ApoB and LDL-C or non-HDL-C categories in relation to risk of AP

From: Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease

 

No. progressors/N

Unadjusted

OR (95%CI)

P

Model 1

OR (95%CI)

P

Model 2

OR (95%CI)

P

ApoB

       

Low tertile

49/180

Ref.

 

Ref.

 

Ref.

 

Medium tertile

63/182

1.42 (0.90, 2.22)

0.129

1.83 (1.14, 2.96)

0.013

1.93 (1.18, 3.16)

0.009

      

1.92 (1.15, 3.19)#

0.012#

High tertile

72/182

1.75 (1.12, 2.72)

0.013

2.23 (1.38, 3.61)

0.001

2.08 (1.27, 3.43)

0.004

      

2.05 (1.17, 3.60)#

0.013#

LDL-C

       

Low tertile

60/181

Ref.

 

Ref.

 

Ref.

 

Medium tertile

61/186

0.98 (0.64, 1.52)

0.943

1.20 (0.76, 1.90)

0.434

1.17 (0.73, 1.87)

0.521

High tertile

63/177

1.11 (0.72, 1.72)

0.626

1.45 (0.91, 2.31)

0.115

1.43 (0.88, 2.32)

0.151

ApoB/LDL-C

       

Low apoB/Low LDL-C

47/181

Ref.

 

Ref.

 

Ref.

 

Low apoB/High LDL-C

28/82

1.48 (0.84, 2.60)

0.175

1.75 (0.97, 3.16)

0.065

1.72 (0.94, 3.16)

0.079

High apoB/Low LDL-C

33/91

1.62 (0.94, 2.79)

0.080

2.10 (1.17, 3.75)

0.012

2.05 (1.11, 3.78)

0.022

High apoB/High LDL-C

76/190

1.90 (1.22, 2.96)

0.004

2.42 (1.50, 3.91)

< 0.001

2.32 (1.42, 3.81)

0.001

ApoB/Non-HDL-C

       

Low apoB/Low non-HDL-C

56/197

Ref.

 

Ref.

 

Ref.

 

Low apoB/High non-HDL-C

19/66

1.02(0.55, 1.89)

0.955

1.29 (0.67, 2.47)

0.443

1.18 (0.61, 2.30)

0.624

High apoB/Low non-HDL-C

32/75

1.87 (1.08, 3.26)

0.026

2.16 (1.20, 3.89)

0.010

2.07 (1.12, 3.82)

0.020

High apoB/High non-HDL-C

77/206

1.50 (0.99, 2.29)

0.057

2.01 (1.27, 3.18)

0.003

1.88 (1.17, 3.02)

0.009

  1. Model 1: Adjusted for age, sex, BMI, hypertension, diabetes mellitus, initial obstructive CAD, and smoking status
  2. Model 2: Model 1 + HbA1c, HDL-C, Lipoprotein(a), initial GS, baseline statins, and β blocker used
  3. #Owing to its clinical importance, baseline LDL-C level was additionally included when adjusting for confounding factors in Model 2 to assess the performance of baseline apoB in predicting AP.
  4. ApoB apolipoprotein B, BMI body mass index, CAD coronary artery disease, HbA1c hemoglobinA1c, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, GS Gensini Score, OR odds ratio, CI confidence interval, AP angiographic progression
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X